Sunshine Biopharma Inc (SBFM)

[megabandp]

Latest PR on their anti-cancer drug

October 17, 2019
SUNSHINE BIOPHARMA INITIATES Adva-27a XENOGRAFT STUDIES IN MICE CARRYING
DIFFERENT TYPES OF HUMAN CANCER

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets:
“SBFM”), a pharmaceutical company focused on the research, development and
commercialization of drugs for the treatment of aggressive forms of cancer, today announced
that it has initiated studies of Adva-27a in xenograft mice. In these studies, specifically
engineered mice which have developed tumors following injection with patient derived cancer
cells are treated with Adva-27a to assess the ability of the drug to shrink the tumors. Among the
different types of patient derived cancer types being studied are Pancreatic Cancer, Breast
Cancer, Small-Cell Lung Cancer and Uterine Sarcoma.

About Adva-27a
Adva-27a is Sunshine Biopharma’s proprietary anticancer compound. In vitro tests conducted
on Adva-27a have demonstrated the drug’s effectiveness at destroying Multidrug Resistant
Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer
cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to
be conducted at McGill University’s Jewish General Hospital in Montreal, Canada.